First-in-human, phase I study of PF-06753512, a vaccine-based immunotherapy regimen (PrCa VBIR), in biochemical relapse (BCR) and metastatic castration-resistant prostate cancer (mCRPC) Meeting Abstract
| Authors: | Autio, K. A.; Higano, C. S.; Nordquist, L. T.; Appleman, L. J.; Zhang, T.; Zhu, X.; Babiker, H. M.; Vogelzang, N. J.; Prasad, S.; Schweizer, M. T.; Billotte, S.; Binder, J.; Cavazos, N.; Li, R.; Chan, K.; Cho, H.; Dermyer, M.; Hollingsworth, R.; Kern, K. A.; Petrylak, D. P. |
| Abstract Title: | First-in-human, phase I study of PF-06753512, a vaccine-based immunotherapy regimen (PrCa VBIR), in biochemical relapse (BCR) and metastatic castration-resistant prostate cancer (mCRPC) |
| Meeting Title: | 2021 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 39 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2021 Jun 4-8 |
| Meeting Location: | Virtual |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2021-05-20 |
| Language: | English |
| ACCESSION: | WOS:000708120601133 |
| DOI: | 10.1200/JCO.2021.39.15_suppl.2612 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 2612 -- Source: Wos |
